Effects of Co-administration of clenbuterol and testosterone propionate on skeletal muscle in paraplegic mice

Journal of Neurotrauma

Volumn 27, Issue 6, 2010, Pages 1129-1142

  Ung, Roth Visal ^a   Rouleau, Pascal ^a   Guertin, Pierre A ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b Nordic Life Science Pipeline   (Canada)

Author keywords

locomotor function; recovery; spinal cord injury; therapeutic approaches for the treatment of CNS injury

Indexed keywords

CLENBUTEROL; TESTOSTERONE PROPIONATE; ABKHAZOMYCIN; ANDROGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MYOSIN HEAVY CHAIN; POLYENE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; EXTENSOR DIGITORUM LONGUS MUSCLE; FAST MUSCLE FIBER; HINDLIMB; LOCOMOTION; MALE; MONOTHERAPY; MOTOR PERFORMANCE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PARAPLEGIA; PHENOTYPE; SKELETAL MUSCLE; SLOW MUSCLE FIBER; SOLEUS MUSCLE; THORACIC SPINAL CORD; WEIGHT REDUCTION; ANALYSIS OF VARIANCE; ANIMAL; BODY WEIGHT; DRUG EFFECTS; DRUG INTERACTION; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; RANDOMIZATION;

ADRENERGIC BETA-AGONISTS; ANALYSIS OF VARIANCE; ANDROGENS; ANIMALS; BODY WEIGHT; CLENBUTEROL; DRUG INTERACTIONS; IMMUNOHISTOCHEMISTRY; MICE; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MYOSIN HEAVY CHAINS; PARAPLEGIA; POLYENES; RANDOM ALLOCATION; TESTOSTERONE PROPIONATE;

EID: 77953956724     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/neu.2009.1211     Document Type: Article

References (73)

1. Agbenyega, E.T., Morton, R.H., Hatton, P.A., and Wareham, A.C. (1995). Effect of the beta 2-adrenergic agonist clenbuterol on the growth of fast- and slow-twitch skeletal muscle of the dystrophic (C57BL6J dy2J/dy2J) mouse. Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. 111, 397-403.
2. Anderson, G., and Wilkins, E. (1977). A trial of clenbuterol in bronchial asthma. Thorax 32, 717-719.
3. Antri, M., Orsal, D., and Barthe, J.Y. (2002). Locomotor recovery in the chronic spinal rat: effects of long-term treatment with a 5-HT2 agonist. Eur. J. Neurosci. 16, 467-476. (Pubitemid 35471865)
4. Apseloff, G., Girten, B., Walker, M., Shepard, D.R., Krecic, M.E., Stern, L.S., and Gerber, N. (1993). Aminohydroxybutane bisphosphonate and clenbuterol prevent bone changes and retard muscle atrophy respectively in tail-suspended rats. J. Pharmacol. Exp. Ther. 264, 1071-1078.
5. Axell, A.M., MacLean, H.E., Plant, D.R., Harcourt, L.J., Davis, J.A., Jimenez, M., Handelsman, D.J., Lynch, G.S., and Zajac, J.D. (2006). Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice. Am. J. Physiol. Endocrinol. Metab. 291, E506-E516.
6. Bauman, W.A., and Spungen, A.M. (2000). Metabolic changes in persons after spinal cord injury. Phys. Med. Rehabil. Clin. N. Am. 11, 109-140.
7. Bauman, W.A., Kahn, N.N., Grimm, D.R., and Spungen, A.M. (1999). Risk factors for atherogenesis and cardiovascular autonomic function in persons with spinal cord injury. Spinal Cord 37, 601-616.
8. Basso, D.M., Fisher, L.C., Anderson, A.J., Jakeman, L.B., McTigue, D.M., and Popovich, P.G. (2006). Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J. Neurotrauma 23, 635-659.
9. Benson, D.W., Foley-Nelson, T., Chance, W.T., Zhang, F.S., James, J.H., and Fischer, J.E. (1991). Decreased myofibrillar protein breakdown following treatment with clenbuterol. J. Surg. Res. 50, 1-5.
10. Bhasin, S., Storer, T.W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T.J., Tricker, R., Shirazi, A., and Casaburi, R. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med. 335, 1-7.
11. Bloomfield, S.A., Girten, B.E., and Weisbrode, S.E. (1997). Effects of vigorous exercise training and beta-agonist administration on bone response to hindlimb suspension. J. Appl. Physiol. 83, 172-178.
12. Brown, T.J., Khan, T., and Jones, K.J. (1999). Androgen induced acceleration of functional recovery after rat sciatic nerve injury. Restor. Neurol. Neurosci. 15, 289-295.
13. Carter, W.J., Dang, A.Q., Faas, F.H., and Lynch, M.E. (1991). Effects of clenbuterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats. Metabolism 40, 855-860.
14. Choo, J.J., Horan, M.A., Little, R.A., and Rothwell, N.J. (1992). Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. Am. J. Physiol. 263, E50-E56.
15. Choong, K., Lakshman, K.M., and Bhasin, S. (2008). The physiological and pharmacological basis for the ergogenic effects of androgens in elite sports. Asian J. Androl. 10, 351-363.
16. Clark, M.J., Petroski, G.F., Mazurek, M.O., Hagglund, K.J., Sherman, A.K., Lammy, A.B., Childers, M.K., and Acuff, M.E. (2008). Testosterone replacement therapy and motor function in men with spinal cord injury: a retrospective analysis. Am. J. Phys. Med. Rehabil. 87, 281-284.
17. Cox, S.A., Weiss, S.M., Posuniak, E.A., Worthington, P., Prioleau, M., and Heffley, G. (1985). Energy expenditure after spinal cord injury: an evaluation of stable rehabilitating patients. J. Trauma 25, 419-423.
18. Criswell, D.S., Powers, S.K., and Herb, R.A. (1996). Clenbuterolinduced fiber type transition in the soleus of adult rats. Eur. J. Appl. Physiol. Occup. Physiol. 74, 391-396.
19. Cruse, J.M., Lewis, R.E., Dilioglou, S., Roe, D.L., Wallace, W.F., and Chen, R.S. (2000). Review of immune function, healing of pressure ulcers, and nutritional status in patients with spinal cord injury. J. Spinal Cord Med. 23, 129-135.
20. Dudgeon, W.D., Phillips, K.D., Carson, J.A., Brewer, R.B., Durstine, J.L., and Hand, G.A. (2006). Counteracting muscle wasting in HIV-infected individuals. HIV Med. 7, 299-310.
21. Ferrando, A.A., Sheffield-Moore, M., Wolf, S.E., Herndon, D.N., and Wolfe, R.R. (2001). Testosterone administration in severe burns ameliorates muscle catabolism. Crit. Care Med. 29, 1936-1942.
22. Fong, A.J., Cai, L.L., Otoshi, C.K., Reinkensmeyer, D.J., Burdick, J.W., Roy, R.R., and Edgerton, V.R. (2005). Spinal cord-transected mice learn to step in response to quipazine treatment and robotic training. J. Neurosci. 25, 11738-11747.
23. Forrest, G.F., Sisto, S.A., Barbeau, H., Kirshblum, S.C., Wilen, J., Bond, Q., Bentson, S., Asselin, P., Cirnigliaro, C.M., and Harkema, S. (2008). Neuromotor and musculoskeletal responses to locomotor training for an individual with chronic motor complete AIS-B spinal cord injury. J. Spinal Cord Med. 31, 509-521.
24. Gerrits, H.L., De Haan, A., Sargeant, A.J., van Langen, H., and Hopman, M.T. (2001). Peripheral vascular changes after electrically stimulated cycle training in people with spinal cord injury. Arch. Phys. Med. Rehabil. 82, 832-839.
25. Giangregorio, L., and McCartney, N. (2006). Bone loss and muscle atrophy in spinal cord injury: Epidemiology, fracture prediction, and rehabilitation strategies. J. Spinal Cord Med. 29, 489-500.
26. Graham, M.R., Davies, B., Grace, F.M., Kicman, A., and Baker, J.S. (2008). Anabolic steroid use: patterns of use and detection of doping. Sports Med. 38, 505-525.
27. Gregory, C.M., Vandenborne, K., Huang, H.F., Ottenweller, J.E., and Dudley, G.A. (2003). Effects of testosterone replacement therapy on skeletal muscle after spinal cord injury. Spinal Cord 41, 23-28.
28. Guertin, P.A. (2005). Semiquantitative assessment of hindlimb movement recovery without intervention in adult paraplegic mice. Spinal Cord 43, 162-166.
29. Herbst, K.L., and Bhasin, S. (2004). Testosterone action on skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 7, 271-277.
30. Herrera, N.M., Jr., Zimmerman, A.N., Dykstra, D.D., and Thompson, L.V. (2001). Clenbuterol in the prevention of muscle atrophy: a study of hindlimb-unweighted rats. Arch. Phys. Med. Rehabil. 82, 930-934.
31. Huang, H.F., Li, M.T., Giglio, W., Anesetti, R., Ottenweller, J.E., and Pogach, L.M. (1999). The detrimental effects of spinal cord injury on spermatogenesis in the rat is partially reversed by testosterone, but enhanced by follicle-stimulating hormone. Endocrinology 140, 1349-1355.
32. Ichiyama, R.M., Courtine, G., Gerasimenko, Y.P., Yang, G.J., van den Brand, R., Lavrov, I.A., Zhong, H., Roy, R.R., and Edgerton, V.R. (2008). Step training reinforces specific spinal locomotor circuitry in adult spinal rats. J. Neurosci. 28, 7370-7375.
33. Junker, V., Becker, A., Huhne, R., Zembatov, M., Ravati, A., Culmsee, C., and Krieglstein, J. (2002). Stimulation of betaadrenoceptors activates astrocytes and provides neuroprotection. Eur. J. Pharmacol. 446, 25-36.
34. Kahn, N.N., Sinha, A.K., Spungen, A.M., and Bauman, W.A. (2006). Effects of oxandrolone, an anabolic steroid, on hemostasis. Am. J. Hematol. 81, 95-100.
35. Katznelson, L., Finkelstein, J.S., Schoenfeld, D.A., Rosenthal, D.I., Anderson, E.J., and Klibanski, A. (1996). Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. 81, 4358-4365.
36. Kearns, C.F., McKeever, K.H., Malinowski, K., Struck, M.B., and Abe, T. (2001). Chronic administration of therapeutic levels of clenbuterol acts as a repartitioning agent. J. Appl. Physiol. 91, 2064-2070.
37. Koopman, R., Ryall, J.G., Church, J.E., and Lynch, G.S. (2009). The role of beta-adrenoceptor signalling in skeletal muscle: therapeutic implications for muscle wasting disorders. Curr. Opin. Clin. Nutr. Metab. Care 12, 601-606.
38. Krause, P., Szecsi, J., and Straube, A. (2008). Changes in spastic muscle tone increase in patients with spinal cord injury using functional electrical stimulation and passive leg movements. Clin. Rehabil. 22, 627-634.
39. Kujawa, K.A., Kinderman, N.B., and Jones, K.J. (1989). Testosterone-induced acceleration of recovery from facial paralysis following crush axotomy of the facial nerve in male hamsters. Exp. Neurol. 105, 80-85.
40. Landry, E., Frenette, J., and Guertin, P. A. (2004). Body weight, limb size, and muscular properties of early paraplegic mice. J Neurotrauma 21, 1008-1016.
41. Landry, E.S., Lapointe, N.P., Rouillard, C., Levesque, D., Hedlund, P.B., and Guertin, P.A. (2006). Contribution of spinal 5-HT1A and 5-HT7 receptors to locomotor-like movement induced by 8-OH-DPAT in spinal cord-transected mice. Eur. J. Neurosci. 24, 535-546.
42. Lapointe, N.P., Ung, R.V., Bergeron, M., Cote, M., and Guertin, P.A. (2006). Strain-dependent recovery of spontaneous hindlimb movement in spinal cord transected mice (CD1, C57BL/ 6, BALB/c). Behav. Neurosci. 120, 826-834.
43. Lieber, R.L., Friden, J.O., Hargens, A.R., and Feringa, E.R. (1986b). Long-term effects of spinal cord transection on fast and slow rat skeletal muscle. II. Morphometric properties. Exp. Neurol. 91, 435-448.
44. Lieber, R.L, Johansson, C.B., Vahlsing, H.L., Hargens, A.R., and Feringa, E.R. (1986a). Long-term effects of spinal cord transection on fast and slow rat skeletal muscle. 1. Contractile properties. Exp. Neurol. 91, 423-434.
45. Lynch, G.S., and Ryall, J.G. (2008). Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol. Rev. 88, 729-767.
46. Lynch, G.S., Hinkle, R.T., and Faulkner, J.A. (1999). Year-long clenbuterol treatment of mice increases mass, but not specific force or normalized power, of skeletal muscles. Clin. Exp. Pharmacol. Physiol. 26, 117-120.
47. MacLennan, P.A., and Edwards, R.H. (1989). Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy. Biochem. J. 264, 573-579.
48. Modlesky, C.M., Majumdar, S., Narasimhan, A., and Dudley, G.A. (2004). Trabecular bone microarchitecture is deteriorated in men with spinal cord injury. J. Bone Miner. Res. 19, 48-55.
49. Oishi, Y., Imoto, K., Ogata, T., Taniguchi, K., Matsumoto, H., and Roy, R.R. (2002). Clenbuterol induces expression of multiple myosin heavy chain isoforms in rat soleus fibres. Acta Physiol. Scand. 176, 311-318.
50. Pansarasa, O., D'Antona, G., Gualea, M.R., Marzani, B., Pellegrino, M.A., and Marzatico, F. (2002). "Oxidative stress": effects of mild endurance training and testosterone treatment on rat gastrocnemius muscle. Eur. J. Appl. Physiol. 87, 550-555.
51. Picard, S., Lapointe, N.P., Brown, J.P., and Guertin, P.A. (2008). Histomorphometric and densitometric changes in the femora of spinal cord transected mice. Anat. Rec. (Hoboken) 291, 303-307.
52. Picquet, F., De-Doncker, L., and Falempin, M. (2004). Enhancement of hybrid-fiber types in rat soleus muscle after clenbuterol administration during hindlimb unloading. Can. J. Physiol. Pharmacol. 82, 311-318.
53. Rouleau, P., Ung, R.V., Lapointe, N.P., and Guertin, P.A. (2007). Hormonal and immunological changes in mice after spinal cord injury. J. Neurotrauma 24, 367-378.
54. Ryall, J.G., Gregorevic, P., Plant, D.R., Sillence, M.N., and Lynch, G.S. (2002). Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R1386-R1394.
55. Sinha-Hikim, I., Artaza, J., Woodhouse, L., Gonzalez-Cadavid, N., Singh, A.B., Lee, M.I., Storer, T.W., Casaburi, R., Shen, R., and Bhasin, S. (2002). Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. Endocrinol. Metab. 283, E154-E164.
56. Shahidi, N.T. (2001). A review of the chemistry, biological action, and clinical applications of anabolic-androgen steroids. Clin. Ther. 23, 1355-1390.
57. Snyder, P.J., Peachey, H., Berlin, J.A., Hannoush, P., Haddad, G., Dlewati, A., Santanna, J., Loh, L., Lenrow, D.A., Holmes, J.H., Kapoor, S.C., Atkinson, L.E., and Strom, B.L. (2000). Effects of testosterone replacement in hypogonadal men. J. Clin. Endocrinol. Metab. 85, 2670-2677.
58. Spungen, A.M., Koehler, K.M., Modeste-Duncan, R., Rasul, M., Cytryn, A.S., and Bauman, W.A. (2001). Nine clinical cases of nonhealing pressure ulcers in patients with spinal cord injury treated with an anabolic agent: a therapeutic trial. Adv. Skin Wound Care 14, 139-144.
59. Spurlock, D.M., McDaneld, T.G., and McIntyre, L.M. (2006). Changes in skeletal muscle gene expression following clenbuterol administration. BMC Genomics 7, 320.
60. Strauss, I., and Lev-Tov, A. (2003). Neural pathways between sacrocaudal afferents and lumbar pattern generators in neonatal rats. J. Neurophysiol. 89, 773-784.
61. Stuermer, E.K., Sehmisch, S., Tezval, M., Tezval, H., Rack, T., Boekhoff, J., Wuttke, W., Herrmann, T.R., Seidlova-Wuttke, D., and Stuermer, K.M. (2009). Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats. World J. Urol. 27, 547-555.
62. Teng, Y.D., Choi, H., Huang, W., Onario, R.C., Frontera, W.R., Snyder, E.Y., and Sabharwal, S. (2006). Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis. Neurosci. Lett. 397, 155-158.
63. Ung, R.V., Lapointe, N.P., Tremblay, C., Larouche, A., and Guertin, P.A. (2007). Spontaneous recovery of hindlimb movement in completely spinal cord transected mice: a comparison of assessment methods and conditions. Spinal Cord 45, 367-379.
64. Yimlamai, T., Dodd, S.L., Borst, S.E., and Park, S. (2005). Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway. J. Appl. Physiol. 99, 71-80.
65. Zehnder, Y., Luthi, M., Michel, D., Knecht, H., Perrelet, R., Neto, I., Kraenzlin, M., Zach, G., and Lippuner, K. (2004). Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporos. Int. 15, 180-189.
66. Zeman, R.J., Feng, Y., Peng, H., and Etlinger, J.D. (1999). Clenbuterol, a beta(2)-adrenoceptor agonist, improves locomotor and histological outcomes after spinal cord contusion in rats. Exp. Neurol. 159, 267-273.
67. Zeman, R.J., Hirschman, A., Hirschman, M.L., Guo, G., and Etlinger, J.D. (1991). Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am. J. Physiol. 261, E285-E289.
68. Zeman, R.J., Peng, H., and Etlinger, J.D. (2004). Clenbuterol retards loss of motor function in motor neuron degeneration mice. Exp. Neurol. 187, 460-467.
69. Zeman, R.J., Peng, H., Danon, M.J., and Etlinger, J.D. (2000). Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle. Muscle Nerve 23, 521-528.
70. Zeman, R.J., Zhang, Y., and Etlinger, J.D. (1997). Clenbuterol, a beta2-adrenoceptor agonist, reduces scoliosis due to partial transection of rat spinal cord. Am. J. Physiol. 272, E712-E715.
71. Zhao, W., Pan, J., Wang, X., Wu, Y., Bauman, W.A., and Cardozo, C.P. (2008a). Expression of the muscle atrophy factor muscle atrophy F-box is suppressed by testosterone. Endocrinology 149, 5449-5460.
72. Zhao, W., Pan, J., Zhao, Z., Wu, Y., Bauman, W.A., and Cardozo, C.P. (2008b). Testosterone protects against dexamethasoneinduced muscle atrophy, protein degradation and MAFbx upregulation. J. Steroid Biochem. Mol. Biol. 110, 125-129.
73. Zhu, Y., Culmsee, C., Roth-Eichhorn, S., and Krieglstein, J. (2001). Beta(2)-adrenoceptor stimulation enhances latent transforming growth factor-beta-binding protein-1 and transforming growth factor-beta1 expression in rat hippocampus after transient forebrain ischemia. Neuroscience 107, 593-602.